Switch theme
Sign up to access all valuation multiples
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
1994
116
Last FY Revenue $43.3M
Last FY EBITDA -$62.7M
$102M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Silence Therapeutics achieved revenue of $43.3M and an EBITDA of -$62.7M.
Silence Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Silence Therapeutics valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $43.3M | XXX | XXX | XXX |
| Gross Profit | XXX | $31.4M | XXX | XXX | XXX |
| Gross Margin | XXX | 73% | XXX | XXX | XXX |
| EBITDA | XXX | -$62.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -145% | XXX | XXX | XXX |
| EBIT | XXX | -$63.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | -146% | XXX | XXX | XXX |
| Net Profit | XXX | -$45.3M | XXX | XXX | XXX |
| Net Margin | XXX | -105% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Silence Therapeutics's stock price is $2.
Silence Therapeutics has current market cap of $239M, and EV of $102M.
See Silence Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $102M | $239M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Silence Therapeutics has market cap of $239M and EV of $102M.
Silence Therapeutics's trades at 2.4x EV/Revenue multiple, and -1.6x EV/EBITDA.
Equity research analysts estimate Silence Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Silence Therapeutics's P/E ratio is not available.
See valuation multiples for Silence Therapeutics and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $239M | XXX | $239M | XXX | XXX | XXX |
| EV (current) | $102M | XXX | $102M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -1.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -5.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSilence Therapeutics's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.8M for the same period.
Silence Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Silence Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Silence Therapeutics and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -145% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 157% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 219% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Silence Therapeutics acquired XXX companies to date.
Last acquisition by Silence Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Silence Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Silence Therapeutics founded? | Silence Therapeutics was founded in 1994. |
| Where is Silence Therapeutics headquartered? | Silence Therapeutics is headquartered in United States of America. |
| How many employees does Silence Therapeutics have? | As of today, Silence Therapeutics has 116 employees. |
| Who is the CEO of Silence Therapeutics? | Silence Therapeutics's CEO is Mr. Craig A. Tooman. |
| Is Silence Therapeutics publicy listed? | Yes, Silence Therapeutics is a public company listed on PINX. |
| What is the stock symbol of Silence Therapeutics? | Silence Therapeutics trades under SLNCF ticker. |
| When did Silence Therapeutics go public? | Silence Therapeutics went public in 2007. |
| Who are competitors of Silence Therapeutics? | Similar companies to Silence Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Silence Therapeutics? | Silence Therapeutics's current market cap is $239M |
| Is Silence Therapeutics profitable? | Yes, Silence Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
